Exact Sciences Corporation Website

Exact Sciences Corporation

NasdaqCM-EXAS

Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

  • Name

    Exact Sciences Corporation

  • CEO

    Kevin T. Conroy

  • Website

    www.exactsciences.com

  • Sector

    Biotechnology

  • Year Founded

    1995

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Cologuard’s staying power remains underappreciated, as its superior detection of precancerous lesions compared with liquid biopsies should be viewed favorably by physicians and payers.

  • Exact in-licensed Freenome's CRC blood-based screening test, which should allow it to maintain competitive market share if this modality proves to be far more popular than stool-based testing.

  • Exact has a healthy slate of new products, including Cologuard Plus, Cancerguard (MCED), and Oncodetect (MRD for CRC).

Bears Say

  • Exact's path to profitability and positive free cash flow depends on the speed of Cologuard's sales ramp and the company's ability to realize economies of scale.

  • Cologuard sales will likely face severe headwinds if blood-based tests are ultimately included in US screening recommendations.

  • Molecular diagnostics is a nascent market and many of the product types, including MCED testing and MRD testing, could have long and uncertain sales ramps.

Source: Morningstar Analysis - Nov 20, 2025

What's happening

Nov 1, 2025 - Dec 3, 2025

Exact Sciences Corp Soars 56.4% Amid Acquisition Buzz and Strong Earnings

  • Exact Sciences Corp's acquisition by Abbott Laboratories for $105 per share has driven significant investor enthusiasm.
  • The company reported Q3 2025 revenues of $850.74 million, marking a 20% year-over-year increase.
  • Despite minor fluctuations due to executive share sales, overall market sentiment remains bullish on EXAS stock.

Over the past month, Exact Sciences Corp (EXAS) experienced a remarkable performance surge of 56.4%. This growth was primarily fueled by the announcement that Abbott Laboratories would acquire EXAS for $105 per share, equating to an equity value of approximately $21 billion. Following this news, EXAS shares spiked over 17% on the day it was announced as investors reacted positively to the strategic implications for cancer diagnostics and screening solutions.

In addition to acquisition news, Exact Sciences delivered strong financial results for Q3 2025 with revenues reaching $850.74 million—a notable year-over-year increase of 20%. These results exceeded analyst expectations and prompted the company to raise its full-year revenue guidance, indicating confidence in sustained growth within key business segments such as Cologuard and Oncotype DX tests.

While there were some bearish sentiments reflected through minor price fluctuations attributed to executive share sales and mixed adjustments in analyst ratings earlier in November, these concerns were largely overshadowed by positive market reactions stemming from both earnings reports and acquisition discussions. Analysts maintained favorable outlooks on EXAS’s future potential despite slight downgrades from certain firms.

The excitement surrounding the acquisition also generated considerable social media buzz that further amplified investor interest leading up to the official announcement date. As a result of these developments combined with robust operational metrics recently reported, Exact Sciences demonstrated resilience against broader market trends while outperforming not only the S&P 500—which returned just 0.2%—but also surpassing sector benchmarks; specifically outpacing Health Care (XLV) sector performance by an impressive margin of 49.4%.

NasdaqCM:EXAS